Ownership Changes and GMP Compliance: FDA Emphasis

The FDA confirms that changes in ownership of a pharmaceutical manufacturer can impact compliance with current Good Manufacturing Practices (cGMP). Under its cGMP for the 21st Century initiative, the FDA adopted a risk-based inspection system, specifically flagging “recent ownership changes” as a criterion for selecting facilities for review.

A recent warning letter to Seaway Pharma Inc. illustrates this approach. Despite new ownership, the production facility and key management remained unchanged, and repeated inspections revealed persistent deficiencies in quality control and process validation. The FDA determined that management oversight was inadequate, and the company failed to meet quality commitments communicated to both previous and current owners.

The FDA required the company to assess all manufacturing activities, ensure compliance with regulatory standards, and conduct a comprehensive “six-system” audit under 21 CFR 211.34 with a consultant, referencing the 2006 Quality Systems Approach guidance. Contract manufacturers remain fully responsible for ensuring drug safety, identity, strength, quality, and purity.

This underscores that ownership changes can trigger focused FDA scrutiny.

14-01-2026